No Data
Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
Instil Bio to Present at Morgan Stanley Global Healthcare Conference
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapie
Baird Lowers Price Target on Instil Bio to $31 From $34, Maintains Outperform Rating
09:29 AM EDT, 09/06/2022 (MT Newswires) -- Instil Bio (TIL) has an average rating of buy and price targets ranging from $8 to $31, according to analysts polled by Capital IQ. (MT Newswires covers equi
Instil Bio Price Target Cut to $31.00/Share From $34.00 by Baird
Instil Bio Price Target Cut to $31.00/Share From $34.00 by Baird
Instil Bio Is Maintained at Outperform by Baird
Instil Bio Is Maintained at Outperform by Baird
Baird Maintains Outperform on Instil Bio, Lowers Price Target to $31
Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $34 to $31.
Instil Bio Appoints Tim Moore as COO
Instil Bio (NASDAQ:TIL) has appointed Tim Moore to the role of COO. Mr. Moore most recently served as the President and COO of PACT Pharma, a cell therapy company focusing on neo-antigen directed TCR-
Press Release: Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ: TIL), a clinical-stage biopharmaceutical compa
Morgan Stanley Adjusts Instil Bio's Price Target to $8 From $9, Maintains Equalweight Rating
09:26 AM EDT, 08/24/2022 (MT Newswires) -- Instil Bio (TIL) has an average rating of buy and price targets ranging from $8 to $34, according to analysts polled by Capital IQ. (MT Newswires covers equi
Instil Bio Is Maintained at Equal-Weight by Morgan Stanley
Instil Bio Is Maintained at Equal-Weight by Morgan Stanley
Loading...
